Corporate overview
Caprion’s leading and proprietary proteomics discovery technologies - CellCarta® - enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly reduce risk and enhance clinical development productivity and decision making in pharmaceutical research.
CellCarta® Discovery Platform
Caprion’s proteomics discovery platform - CellCarta® - is the leading means for profiling proteins in solid tissues and plasma. CellCarta® is a proprietary, state-of-the-art proteomics technology platform that serves as an engine for unparalleled disease target identification, predictive medicine and the creation of a proprietary therapeutic product pipeline. The power of Caprion’s technology has been successfully leveraged to secure multiple, platform-validating, revenue generating partnerships surrounding oncology therapeutic target identification and clinical biomarker discovery.